South Korea’s biopharmaceutical company Celltrion Inc. announced on Wednesday that it signed a joint research agreement with domestic startup Cyron Therapeutics for the development of a multi-specific antibody drug.
Multi-specific antibody refer to pharmaceuticals that simultaneously bind to multiple different antigens. For example, one drug acts on both immune cells and cancer cells simultaneously, enhancing immunity and targeting cancer cells.
Under the agreement, Cyron will develop trispecific or more multi-specific antibody that bind to the antigens offered by Celltrion. The contract period is three years and the total contract amount, including upfront payments and milestone fees, is up to 1.16 trillion won ($882 million).
Through this agreement, Celltrion aims to strengthen its competitiveness in the anticancer pipeline. The company plans to diversify its portfolio through a two-track strategy: in-house development of anticancer drugs and winning the licenses for external products.
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for CT-P42, a biosimilar of the eye treatment Eylea (ingredient Aflibercept)Based on the results of Phase 3 clinical trials worldwide of CT-P42, Cellt
Celltrion Healthcare's Remsima South Korea's Celltrion Healthcare Co. announced on Friday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for the Brazilian federal government for three consecutive years. The company is set to supply 360,000 vials of Remsima
Celltrion's plant in South Korea South Korean pharmaceutical giant Celltrion Inc. logged record quarterly earnings on the strong performance of its key biosimilar products while expecting its merger with sales affiliates to help the group meet long-term targets.Celltrion Inc. said on Tuesday it
Celltrion founder and Chairman Seo Jung-jin reveals the company's business strategy at its shareholders meeting where its merger with Celltrion Healthcare was approved South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its thre
South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient infliximab, American name Zymfentra) from the US Food and Drug Administration (FDA).Zymfentra is Celltrion's first new drug approved by the FDA. Th